Krebs Biochemicals Peer Comparison

NSE: KREBSBIO | BSE: 524518

₹51.85

₹-5.63 (-9.79%)

As on 23-Oct-2026IST

Market cap

₹114 Cr

Revenue (TTM)

₹25 Cr

P/E Ratio

P/B Ratio

-0.7

Div. Yield

0 %

Edit

	Krebs Biochemicals	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Market cap (₹ Cr)	114	33,547	24,280	15,313	12,856
Revenue (₹ Cr)	25	9,683	2,372	2,590	1,108
Net Profit (₹ Cr)	-14.10	1,018.97	497.77	603.02	270.18
Net Margin (%)	-51.43	10.47	20.72	22.63	23.29
RoE (%)	--	21.30	28.49	19.61	14.45
Price to Earnings	--	33.17	48.78	25.39	46.68
Price-To-Book	-0.69	6.41	12.01	4.39	6.20

Income Statement (₹ Cr)

	Krebs Biochemicals	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Operating Revenue	25.23	9,683.45	2,371.81	2,590.40	1,108.39
Total Income	27.41	9,730.84	2,402.61	2,664.23	1,159.90
Total Expenditure	27.77	7,739.53	1,608.91	1,753.71	720.01
EBITDA	-2.54	1,943.92	762.90	836.69	388.38
Depreciation	6.41	425.10	98.11	78.88	74.78
EBIT	-8.95	1,518.82	664.79	757.81	313.60
Interest	7.32	148.45	26.33	5.43	0.26
Other Income	2.17	47.39	30.80	73.83	51.50
Exceptional Items	0.00	-27.85	0.00	-25.66	-3.28
Profit before Tax	-14.10	1,389.91	669.26	800.55	361.56
Provision for Tax	0.00	370.94	171.48	197.53	91.39
Profit after Tax	-14.10	1,018.97	497.77	603.02	270.18

	Krebs Biochemicals	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Shareholder's Funds	-162.75	4,950.03	1,874.47	3,332.13	2,017.06
Minority Interest	0.00	-7.58	0.00	0.00	2.51
Non-Current Liabilities	212.94	723.57	345.47	142.73	50.51
Current Liabilities	113.07	3,912.24	710.20	508.04	169.08
Total Liabilities	163.25	9,514.48	2,930.14	4,157.10	2,231.79

	Krebs Biochemicals	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Non-Current Assets	143.30	3,392.16	1,290.62	1,321.38	957.22
Current Assets	9.62	5,612.10	1,483.13	2,649.36	1,250.11
Total Assets	163.25	9,514.48	2,930.14	4,157.10	2,231.79
Total Debt*	224.84	1,204.08	196.61	0.00	0.00
Net Current Assets	-103.44	1,699.86	772.93	2,141.33	1,081.04
Contingent Liabilities	9.26	258.92	13.18	4.82	3.76

	Krebs Biochemicals	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Cash From Operating Activities	-1.92	943.55	346.68	565.41	266.88
Cash Flow from Investing Activities	-3.64	-1,193.06	-423.73	-570.15	-142.72
Cash from Financing Activities	5.54	343.43	20.98	-64.34	-112.88
Net Cash Inflow / Outflow	-0.01	93.92	-56.08	-69.08	11.28

	Krebs Biochemicals	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
ROCE (%)	-15.38	25.25	27.50	24.61	18.04
ROE (%)	0.00	21.30	28.49	19.61	14.45
ROA (%)	-8.48	11.42	19.48	16.31	12.66
EBIT Margin (%)	-35.47	15.68	28.03	29.25	28.29
Net Margin (%)	-51.43	10.47	20.72	22.63	23.29
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Krebs Biochemicals	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Revenue Growth (%)	-29.72	18.36	78.33	7.93	-6.72
EBIT Growth (%)	58.40	30.43	303.07	19.88	-26.64
Net Profit Growth (%)	47.97	32.39	182.61	21.66	-24.38
EPS Growth (%)	47.97	36.68	277.72	25.42	-21.99
Book Value Growth (%)	-11.29	11.36	22.95	18.43	11.27

	Krebs Biochemicals	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Price / Earnings	-8.11	32.49	48.78	24.59	46.28
Price / Book Value	-0.69	6.41	12.01	4.39	6.20
Dividend Yield (%)	0.00	0.20	0.18	0.40	0.61
EV/EBITDA	-133.61	17.80	31.62	17.37	32.03
Market Cap (₹ Cr)	86.26	30,257.56	15,412.11	11,956.86	10,627.92

	Krebs Biochemicals	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debt to Equity	-1.00	0.05	0.09	0.00	0.00
Short term debt to equity ratio	-0.38	0.16	--	--	--
Current Ratio	0.09	1.43	2.09	5.21	7.39
Quick Ratio	0.03	0.82	1.37	3.85	5.46
Interest Coverage	-0.93	10.36	26.41	148.49	1,386.30

	Krebs Biochemicals	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Concord Biotech
Debtors to sales (%)	0.02	26.46	22.82	41.42	41.52
Asset Turnover	0.15	1.09	0.93	0.70	0.52
Receivable days	0.42	88.68	77.32	144.58	169.86
Inventory Days	90.24	84.11	80.83	96.67	97.92
Payable days	0.00	176.65	125.94	135.45	159.68
Cash Conversion Cycle	90.66	-3.86	32.22	105.80	108.11

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.